Gilead Sciences Inc Earnings
The next earnings date for Gilead Sciences Inc has not yet been scheduled.
Analyst Estimates of Gilead Sciences Inc Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Gilead Sciences Inc Earnings: Historical
| 08/04/2026 | After Market | $-6.75 | 4.53% |
| 05/07/2026 | After Market | $2.03 | 6.28% |
| 02/10/2026 | After Market | $1.86 | 2.76% |
| 10/30/2025 | After Market | $2.47 | 15.42% |
| 08/07/2025 | After Market | $2.01 | 3.08% |
| 04/24/2025 | After Market | $1.81 | 1.69% |
| 02/04/2025 | After Market | $1.90 | 11.73% |
| 11/06/2024 | After Market | $2.02 | 30.32% |
| 08/08/2024 | After Market | $2.01 | 25.63% |
| 04/25/2024 | After Market | $-1.32 | 13.16% |
More About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
“Gilead Sciences Inc Earnings” Can Refer to the Gilead Sciences Inc Earnings Date
Some people say “Gilead Sciences Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Gilead Sciences Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Gilead Sciences Inc Stock on the Earnings Date
If you own Gilead Sciences Inc stock (GILD) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Gilead Sciences Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Gilead Sciences Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning Gilead Sciences Inc Options on the Earnings Date
If you own Gilead Sciences Inc options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of Gilead Sciences Inc options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own Gilead Sciences Inc options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for Gilead Sciences Inc. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of Gilead Sciences Inc options often go down. This is sometimes referred to as volatility crush.
Learning More Gilead Sciences Inc Earnings
You can contact us any time if you would like to ask questions about Gilead Sciences Inc earnings or anything else related to the stock market.